VIVO Stock Recent News

Meridian Bioscience Inc (NASDAQ: VIVO) reported a 30% increase in Q2 sales to $111.2 million, the highest in the company's history, with both segments ahead of expectations, beating the consensus of $99.54 million. Revenues from the life science division grew 32% Y/Y to $70.1 million.

Meridian Bioscience, Inc. (NASDAQ:VIVO ) Q2 2022 Earnings Conference Call May 6, 2022 10:00 AM ET Corporate Participants Charlie Wood - Vice President of Investor Relations Jack Kenny - Chief Executive Officer Andy Kitzmiller - Chief Financial Officer Conference Call Participants Dustin Scaringe - William Blair Operator Greetings, and welcome to Meridian Bioscience Fiscal Second Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.

Meridian Bioscience (VIVO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Meridian Bioscience (VIVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Meridian Bioscience's (VIVO) fiscal second-quarter results are likely to reflect continued strength across both its segments.